RAS-targeting small molecules redefine pancreatic cancer treatment

Summary

A Perspective in PLOS Medicine highlights that treatment for pancreatic adenocarcinoma is moving beyond cytotoxic chemotherapy, with recent advances in RAS-targeting small molecule inhibitors reshaping therapeutic paradigms. The authors discuss clinical trial results and the ongoing challenge of treatment resistance.

This is a reviewed summary. Read the complete article at the original source.

Why it matters by industry

• Healthcare & Life Sciences

  Directly relevant to oncology drug development and clinical practice, as it summarizes emerging RAS-targeted therapies for a difficult-to-treat cancer.